Aryplase (Biomarin).
BioMarin is developing Aryplase (BM-102), a recombinant form of the enzyme N-acetylgalactosamine 4-sulfatase, for the potential treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy Syndrome). By November 2003 enrollment for a pivoltal phase III trial was complete.
Yogalingam
Gouri
G
Department of Genetics and Tumor Cell Biology, St Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA. Gouri.yogalingam@stjude.org
D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D009087:Mucopolysaccharidosis VI / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D020051:N-Acetylgalactosamine-4-Sulfatase / Q000235:genetics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000235:genetics / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D020051:N-Acetylgalactosamine-4-Sulfatase